Biomarkers in patients after chemotherapy

Abstract

Along with the rapid development of molecular genetic testing, immunotherapy and targeted antitumor therapy in Oncology, the risk of cardiotoxicity associated with chemotherapy remains a keystone that directly affects the survival and quality of life of patients after therapy. Elevated levels of troponin, BNP/NT-proBNP, myeloperoxidase, and D-dimer have been associated with increased all-cause mortality in cancer patients and have been shown in numerous studies to predict the risk of heart failure and myocardial damage associated with chemotherapy. Specifi diagnostic algorithms are particularly important for risk stratifiation, monitoring, and long-term follow-up of cancer patients receiving chemotherapy. Biomarkers are the basis for diagnosing acute and chronic heart diseases. However, their role in the timely detection and monitoring of cardiotoxicity is not well understood. Thus, clinicians should identify adverse effects at an early stage, seeking to take appropriate preventive measures before the occurrence of a permanent or irreversible dysfunction of the heart. In dynamic cardiology, biomarkers are a key tool for risk assessment, diagnosis, and monitoring of cancer-related cardiotoxicity and cancer therapy. The complex interaction of such branches of medicine as oncology, oncotherapy and cardiology indicates the need for a multi-disciplinary cardio-oncological approach to ensure optimal quality of treatment